These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32340871)

  • 1. Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.
    Saeed O; Colombo PC; Mehra MR; Uriel N; Goldstein DJ; Cleveland J; Connors JM; Najjar SS; Mokadam NA; Bansal A; Crandall DL; Sood P; Jorde UP
    J Heart Lung Transplant; 2020 Jun; 39(6):518-525. PubMed ID: 32340871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
    Uriel N; Colombo PC; Cleveland JC; Long JW; Salerno C; Goldstein DJ; Patel CB; Ewald GA; Tatooles AJ; Silvestry SC; John R; Caldeira C; Jeevanandam V; Boyle AJ; Sundareswaran KS; Sood P; Mehra MR
    Circulation; 2017 May; 135(21):2003-2012. PubMed ID: 28385948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.
    Mehra MR; Netuka I; Uriel N; Katz JN; Pagani FD; Jorde UP; Gustafsson F; Connors JM; Ivak P; Cowger J; Ransom J; Bansal A; Takeda K; Agarwal R; Byku M; Givertz MM; Bitar A; Hall S; Zimpfer D; Vega JD; Kanwar MK; Saeed O; Goldstein DJ; Cogswell R; Sheikh FH; Danter M; Pya Y; Phancao A; Henderson J; Crandall DL; Sundareswaran K; Soltesz E; Estep JD;
    JAMA; 2023 Dec; 330(22):2171-2181. PubMed ID: 37950897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
    Mehra MR; Crandall DL; Gustafsson F; Jorde UP; Katz JN; Netuka I; Uriel N; Connors JM; Sood P; Heatley G; Pagani FD
    Eur J Heart Fail; 2021 Jul; 23(7):1226-1237. PubMed ID: 34142415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.
    Goldstein DJ; Naka Y; Horstmanshof D; Ravichandran AK; Schroder J; Ransom J; Itoh A; Uriel N; Cleveland JC; Raval NY; Cogswell R; Suarez EE; Lowes BD; Kim G; Bonde P; Sheikh FH; Sood P; Farrar DJ; Mehra MR
    JAMA Cardiol; 2020 Apr; 5(4):411-419. PubMed ID: 31939996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial.
    Vidula H; Takeda K; Estep JD; Silvestry SC; Milano C; Cleveland JC; Goldstein DJ; Uriel N; Kormos RL; Dirckx N; Mehra MR
    JACC Heart Fail; 2022 Jul; 10(7):470-481. PubMed ID: 35772857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.
    Mehra MR; Goldstein DJ; Cleveland JC; Cowger JA; Hall S; Salerno CT; Naka Y; Horstmanshof D; Chuang J; Wang A; Uriel N
    JAMA; 2022 Sep; 328(12):1233-1242. PubMed ID: 36074476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study.
    Shah P; Looby M; Dimond M; Bagchi P; Shah B; Isseh I; Rollins AT; Abdul-Aziz AA; Kennedy J; Tang DG; Klein KM; Casselman S; Vermeulen C; Sheaffer W; Snipes M; Sinha SS; O'Connor CM
    JACC Heart Fail; 2024 Sep; 12(9):1540-1549. PubMed ID: 38795110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3.
    Barac YD; Wojnarski CM; Junpaparp P; Jawitz OK; Billard H; Daneshmand MA; Agrawal R; Devore A; Patel CB; Schroder JN; Milano CA
    J Thorac Cardiovasc Surg; 2020 Jul; 160(1):132-139.e1. PubMed ID: 31740114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
    Bansal A; Uriel N; Colombo PC; Narisetty K; Long JW; Bhimaraj A; Cleveland JC; Goldstein DJ; Stulak JM; Najjar SS; Lanfear DE; Adler ED; Dembitsky WP; Somo SI; Crandall DL; Chen D; Connors JM; Mehra MR
    J Heart Lung Transplant; 2019 Aug; 38(8):806-816. PubMed ID: 31147187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin resistance in patients with ventricular assist devices: A follow-up study.
    Flieder T; Blaesen S; Schulte K; Blasberg J; Lauenroth V; Knabbe C; Schramm R; Morshuis M; Gummert J; Birschmann I
    Artif Organs; 2024 Jul; 48(7):781-788. PubMed ID: 38553978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study.
    Mehra MR; Salerno C; Cleveland JC; Pinney S; Yuzefpolskaya M; Milano CA; Itoh A; Goldstein DJ; Uriel N; Gulati S; Pagani FD; John R; Adamson R; Bogaev R; Thohan V; Chuang J; Sood P; Goates S; Silvestry SC
    Circulation; 2018 Oct; 138(18):1923-1934. PubMed ID: 29807933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.
    Saeed O; Shah A; Kargoli F; Madan S; Levin AP; Patel SR; Jermyn R; Guerrero C; Nguyen J; Sims DB; Shin J; D'Alessandro D; Goldstein DJ; Jorde UP
    Circ Heart Fail; 2016 Jan; 9(1):e002296. PubMed ID: 26721914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Among Women and Men.
    Ramu B; Cogswell R; Ravichandran AK; Cleveland J; Mehra MR; Goldstein D; Uriel N; Dirckx N; Ahmed S; Yuzefpolskaya M
    JACC Heart Fail; 2023 Dec; 11(12):1692-1704. PubMed ID: 37831046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin and aspirin versus warfarin alone for prevention of bleeding and thrombotic events in patients with a HeartMate 3™ left ventricular assist device.
    Yi M; Iyer P; Byku M; Hollis IB
    Artif Organs; 2024 Jan; 48(1):98-102. PubMed ID: 37755126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Normalized Ratio Test Frequency in Left Ventricular Assist Device Patients Affects Anticoagulation Quality and Adverse Events.
    Schlöglhofer T; Zapusek L; Wiedemann D; Riebandt J; Wittmann F; Dimitrov K; Angleitner P; Haberl L; Laufer G; Moscato F; Zimpfer D; Schima H
    ASAIO J; 2021 Feb; 67(2):157-162. PubMed ID: 32501824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device.
    Nayak A; Hall SA; Uriel N; Goldstein DJ; Cleveland JC; Cowger JA; Salerno CT; Naka Y; Horstmanshof D; Crandall D; Wang A; Mehra MR
    J Am Coll Cardiol; 2023 Aug; 82(9):771-781. PubMed ID: 37612008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.
    Mehra MR; Cleveland JC; Uriel N; Cowger JA; Hall S; Horstmanshof D; Naka Y; Salerno CT; Chuang J; Williams C; Goldstein DJ;
    Eur J Heart Fail; 2021 Aug; 23(8):1392-1400. PubMed ID: 33932272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Antiplatelet Therapy During Continuous-Flow Left Ventricular Assist Device Support After Thrombotic Hemorrhagic Events.
    Gallo M; Trivedi JR; Mondal NK; Birks EJ; Slaughter MS
    ASAIO J; 2019; 65(7):683-689. PubMed ID: 30585872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of Preoperative Existence of Atrial Fibrillation on Hemocompatibility-Related Adverse Events During Left Ventricular Assist Device Support.
    Imamura T; Kinugawa K; Ono M; Kinoshita O; Fukushima N; Shiose A; Matsui Y; Yamazaki K; Saiki Y; Usui A; Niinami H; Matsumiya G; Arai H; Sawa Y
    Circ J; 2019 May; 83(6):1286-1292. PubMed ID: 31019163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.